Navigation Links
Genomas Presents Drug-Specific Genetic Determinants of Statin Safety and Efficacy at the XV International Symposium on Atherosclerosis

Data Being Used to Develop DNA-Guided Decision Support for Statin Prescription

BOSTON, June 15 /PRNewswire/ -- Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, announced its participation at the prestigious XV International Symposium on Atherosclerosis, a meeting held triennially by the International Atherosclerosis Society. Gualberto Ruano, MD, PhD, President of Genomas, will present "Physiogenomic Contours of Statin Safety and Efficacy," a clinical study examining the differences in response to statin drugs based on individual gene variations.

Statins offer effective strategies to reduce cardiovascular disease and improve survival. However, there are clinically relevant safety risks for some patients. Statin-induced neuro-myopathy (SINM) may present as muscle aches, cramps, weakness, and muscle injury. SINM is more frequent at the higher doses required for treating advanced heart disease, and varies in extent between individual statins and from patient to patient. In previously published studies, over 10% of statin patients experienced neuromuscular side effects, causing disruptions in daily life activities, and reduction in regimen adherence.

In this study, 442 outpatients treated with atorvastatin, rosuvastatin and/or simvastatin were studied in lipid clinics at Hartford Hospital (Hartford, CT) and the University of California, San Francisco. Researchers genotyped 384 SNPs (single nucleotide polymorphisms) from 222 cardiometabolic and neuroendocrine genes with a potential role in determining the safety and efficacy of statins. The study was funded in part by a grant from the National Institute of General Medical Sciences of the National Institutes of Health.

"Contrasting quantitatively how the gene polymorphisms associate with clinical responses, we visualize the 'physiogenomic contours' of statin drugs," said Dr. Ruano. "These contours represent the mechanistic differences among statins, which we plan to use as the foundation for DNA-guided rules for treatment on a patient-individualized basis."


Genomas is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company is developing and testing revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes, and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit for more information.

SOURCE Genomas
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Latest trinational report presents most complete picture of North American industrial pollution
2. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
3. United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging
4. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
5. Frost & Sullivan Presents LG Electronics IRIS With the 2009 Global Iris Recognition Biometrics Market Customer Value Leadership of the Year Award
6. Sound Surgical Technologies Chief Technology Officer Presents Paper on Focused Ultrasound Technology
7. Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting
8. Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
9. Lumenis(R) Presents the SlimLine(TM) GI Laser Fiber: The Latest Advancement in Laser Lithotripsy for Gastroenterology
10. Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook
11. AGA Institute presents cutting-edge research during DDW
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... has prided itself for not only fulfilling the needs of advisers and clients ... an affordable price and providing top-tier customer service. However, there's always room for ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
(Date:11/27/2015)... ... , ... Dr. Thomas Dunlap and Dr. Patrick Coleman , ... Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted ... similar ways and require time-critical intervention to avoid large area heart damage and progressive ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... WASHINGTON , Nov. 25, 2015  The ... Obstetricians and Gynecologists (ACOG), and the March of ... bipartisan Protecting Our Infants Act of 2015 ... the number of newborns born exposed to drugs, ... Since the bill,s introduction, all three organizations have ...
(Date:11/25/2015)... 2015 On Tuesday, November 24, 2015, ... against Wright Medical Technology, Inc. for product liability ... hip implant device, awarded $11 million in favor ... trial and three days of deliberations, the jury ... defectively designed and unreasonably dangerous, and that Wright ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
Breaking Medicine Technology: